The second round of late-breaking clinical trials were presented with results from three studies during the Vascular InterVentional Advances Conference, VIVA23, being held Oct. 30-Nov. 2 in Las Vegas, NV. Notably, results from Abbott’s LIFE-BTK randomized clinical trial (RCT) demonstrated that Esprit BTK (Abbott) reduces disease progression and helps improve medical outcomes compared to balloon angioplasty, the current state of care.
Second Round of Late-Breaking Clinical Trial Results Announced at VIVA23 lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
Second Round of Late-Breaking Clinical Trial Results Announced at VIVA23 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and.
First-on-Podium Data from 20 Vascular and Venous Clinical Trials to Be Presented at The VEINS and VIVA 2023 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.